Research News Archive - 2012

  • Epigenetic analysis of stomach cancer finds new disease subtypes
    October 17, 2012
    Researchers at the Duke-NUS Graduate Medical School in Singapore have identified numerous new subtypes of gastric cancer that are triggered by environmental factors. [Read more]
  • New Test of “Smart Bomb” Drug: A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
    October 2012
    GCF board member Dr. James Ford will be managing the Northern California trial site for a major international study in gastric cancer of a new drug from Roche’s Genentech unit. [Read more]
  • Positive Results For Ramucirumab as Single Agent in Phase III Gastric Cancer Trial
    June 11, 2012
    Eli Lilly announced that the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with metastatic gastric cancer, met its primary endpoint of improved overall survival and also showed prolonged progression-free survival. This trial is the first Phase III data read-out for ramucirumab. [Read more]
  • Analysis Of Rilotumumab (AMG 102) Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer
    May 16, 2012
    Amgen (NASDAQ: AMGN) announced today results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab (AMG 102). [Read more]
  • Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials
    May 15, 2012
    Long-term follow-up of randomised trials of aspirin in prevention of vascular events showed that daily aspirin reduced the incidence of colorectal cancer and several other cancers and reduced metastasis. However, statistical power was inadequate to establish effects on less common cancers and on cancers in women. [Read more]
  • Harnessing immunology to combat tumors
    April 2012
    At the American Association for Cancer Research (AACR) annual meeting in April 2012, researchers were buzzing about tumor immunology, specifically the FDA approval of "CTLA4 antibodies." [Read more]
  • Experts Identify Critical Genes Mutated in Stomach Cancer
    April 2012
    An international team of scientists, led by researchers from the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore and National Cancer Centre of Singapore, has identified hundreds of novel genes that are mutated in stomach cancer, the second-most lethal cancer worldwide. [Read more]
  • Benefits of Dual Chemo Post-Surgery
    January 2012
    A study published in a January 2012 issue of The Lancet pertained to "D2 resection," the surgery that involves removing the primary gastric tumor and lymph nodes around the stomach. The researchers reported that chemotherapy with capecitabine (Xeloda) and oxaliplatin after D2 surgery for patients from Asia with stage 2 or 3 gastric cancer significantly improved disease-free survival compared with D2 surgery alone... [Read more]